SecBot SecBot
PRESS-RELEASE ·Filed Nov 6, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 2/10
Horizonweeks Processed10d 5h ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

This is a routine inducement grant for new hires with no immediate trading implications. Monitor future filings for any larger equity issuances or changes in share count.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$77.93
T+0 close · Nov 6, 2026 · via day close
Latest settled
−0.73%
T+5 · $77.36
Vs SPY
+0.96%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $77.93entry
  2. T+1 · 7d ago +0.95%α +1.32% · $78.67
  3. T+5 · 15h ago −0.73%α +0.96% · $77.36
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma granted 147,578 restricted stock units to 80 new employees as an inducement material to their employment, with vesting starting November 2027. This is a routine equity grant for new hires, not a material financial event.

Key Facts

  • Compensation committee approved equity grants of 147,578 RSUs to 80 new employees on November 5, 2026.
  • One-fourth of each RSU vests on November 16, 2027, with the remainder vesting quarterly thereafter.
  • Grants were made as inducement material to employment under Nasdaq Listing Rule 5635(c)(4).
  • The plan was adopted in November 2019 and amended in February 2023 and December 2023.

Financial Impact

147,578 shares granted; at the snapshot market cap of $15.2B, dilution is approximately 0.01% of outstanding shares (assuming ~1.5B shares outstanding).

dilution

Risk Factors

  • No material risk identified; this is a standard equity grant for new employees.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397881

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Viewing Entry $77.93 Now $77.36 −0.73% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026